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Abstract
Fluorescence correlation spectroscopy (FCS) monitors random movements of fluorescent
molecules in solution, giving information about the number and the size of for example nano-
particles. The canine parvovirus VP2 structural protein as well as N-terminal deletion mutants of
VP2 (-14, -23, and -40 amino acids) were fused to the C-terminus of the enhanced green
fluorescent protein (EGFP). The proteins were produced in insect cells, purified, and analyzed by
western blotting, confocal and electron microscopy as well as FCS. The non-truncated form, EGFP-
VP2, diffused with a hydrodynamic radius of 17 nm, whereas the fluorescent mutants truncated by
14, 23 and 40 amino acids showed hydrodynamic radii of 7, 20 and 14 nm, respectively. These
results show that the non-truncated EGFP-VP2 fusion protein and the EGFP-VP2 constructs
truncated by 23 and by as much as 40 amino acids were able to form virus-like particles (VLPs).
The fluorescent VLP, harbouring VP2 truncated by 23 amino acids, showed a somewhat larger
hydrodynamic radius compared to the non-truncated EGFP-VP2. In contrast, the construct
containing EGFP-VP2 truncated by 14 amino acids was not able to assemble into VLP-resembling
structures. Formation of capsid structures was confirmed by confocal and electron microscopy.
The number of fluorescent fusion protein molecules present within the different VLPs was
determined by FCS. In conclusion, FCS provides a novel strategy to analyze virus assembly and gives
valuable structural information for strategic development of parvovirus-like particles.
Background
Canine parvovirus (CPV) is an autonomous, non-envel-
oped single stranded DNA virus with a diameter of 26 nm.
The icosahedral T = 1 virion contains 60 protein subunits
composed of three different polypeptide chains desig-
nated VP1, VP2, and VP3 [1-7]. VP1 is identical to VP2,
but has 154 additional N-terminal amino acid residues.
The VP3 protein is proteolytically cleaved from VP2 by
removal of about 12 to 15 amino acids from the N-termi-
nus [1,8]. The VP2 protein constitutes most of the capsid
surface while VP1 represents only a small portion of the
capsid composition. It has been shown that VP2 can
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assemble into capsid-like structures [9] and that the struc-
ture of empty CPV capsids had the first 37 residues not
resolved structurally [9]. These structural proteins share a
conserved β-barrel core domain that contains an eight-
stranded, anti-parallel β-barrel motif consisting of two β-
sheets in standard BIDG and CHEF arrangements com-
mon to many viral capsid proteins [10]. This domain
accounts for one third of the amino acid content of each
polypeptide. The other two thirds of the polypeptide
sequence consist of four large loop insertions that form
the surface of the virion.
Viral structures have been mainly characterized by X-ray
crystallography and electron microscopy. Single molecule
detection techniques have arisen for characterization of
macromolecules moving persistently in non-denaturing
physiological conditions. One such emerging method is
fluorescence correlation spectroscopy (FCS) [11-14]. FCS
characterizes interactions and molecular structures
through the dynamic processes of molecules in solution.
Statistical information is extracted from the averaged flu-
orescence intensity fluctuations of fluorescent molecules
diffusing through a small measuring volume of less than
one femtoliter [15,16].
In the present study, 14, 23 and 40 N-terminal amino acid
deletions of the VP2 protein were fused to the C-terminus
of EGFP. The corresponding proteins were produced in
baculovirus infected Spodoptera frugiperda (Sf9) insect
cells, purified and then analyzed by FCS. Results indicated
that the non-fused constructs deleted by 14, 23 and 40
amino acids, and fusion proteins of EGFP-VP2-23 and
EGFP-VP2-40, as well as the non-truncated form of VP2
(EGFP-VP2), were able to form virus-like particles (VLPs)
despite the presence of the bulky EGFP domain. Interest-
ingly, the fluorescent mutant (EGFP-VP2-14) deleted by
only 14 amino acids was not able to form similar struc-
tures.
Results
Expression of the CPV VP2 constructs in insect cells
CPV VP2 and the N-terminal deletions thereof VP2-14,
VP2-23, and VP2-40 as well as the corresponding EGFP
fusions EGFP-VP2, EGFP-VP2-14, EGFP-VP2-23, and
EGFP-VP2-40 (Fig. 1) were produced in Sf9 cells infected
with the respective recombinant baculoviruses AcVP2,
AcVP2-14,  AcVP2-23,  AcVP2-40,  AcEGFP-VP2,  AcEGFP-
VP2-14,  AcEGFP-VP2-23, and AcEGFP-VP2-40. Expres-
sion of all recombinant proteins from cell lysates was con-
firmed by immunoblotting using anti-VP2 and anti-GFP
antibodies and proteins of expected sizes (arrows) were
identified (Figs. 2A and 2B). Particularly in the case of the
EGFP-fusion constructs, some break down products could
also be identified with both antibodies (Figs. 2A and 2B).
For purification of the recombinant proteins, the infected
cell lysates were exposed to sucrose gradient centrifuga-
tion and fractions of the recombinant proteins corre-
sponding to assembled VLPs or capsid-like structures [17]
were further analyzed by immunoblotting using anti-VP2
and anti-GFP antibodies (Figs. 2C and 2D). All proteins
except the EGFP-VP2-14 fusion construct appeared to
assemble into VLPs or resembling structures (Figs. 2C and
2D).
Virus-like particle formation by truncated forms of CPV 
VP2
VLP formation was analyzed by confocal and electron
microscopy studies. Confocal microscopy indicated that
VP2 colocalized with their EGFP fusion partner, but that
the colocalization was not complete (Fig. 3). The anti-
body used here was a mouse monoclonal anti-capsid anti-
body specific for an epitope present only on capsids and
capsid-like structures (A4E3; kind gift from Dr. Colin Par-
rish, Cornell University, Ithaca, NY). Thus, the imperfect
co-localization seen by confocal microscopy (Fig. 3) and
the break down products in the western blots (Fig. 2) are
most likely due to proteolysis of the EGFP-VP2 protein
constructs as seen also in previous studies [18,19]. From
the negatively stained EM micrographs of the VP2 pro-
teins it was obvious, that VP2, VP2-14, VP2-23, VP2-40 as
well as the fusion constructs EGFP-VP2, EGFP-VP2-23 and
EGFP-VP2-40 were able to form structures resembling
VLPs (Fig. 4). All particles appeared to have a diameter of
approximately 26 nm, displaying a typical VP2 or wild-
type CPV structure [18,19]. However, the EGFP-VP2-14
construct appeared not to assemble into similar structures
(Fig. 4).
Characterization of the fluorescent recombinant proteins
The recombinant proteins (EGFP-VP2, EGFP-VP2-14,
EGFP-VP2-23, EGFP-VP2-40) were purified by sucrose
gradient centrifugation prior to further examination. A
total of 37 fractions were collected for each gradient and
the relative fluorescence of each fraction was plotted
against its fraction number (Fig. 5A). The fluorescence sig-
nal seen in this figure indicates that fractions near the top
of the gradient (33–37) contain a large amount of non-
assembled fusion proteins and/or free EGFP, whereas frac-
tions 13–20 showed fluorescent bands visible to the
naked eye for EGFP-VP2, EGFP-VP2-23 and EGFP-VP2-40
and were seen as peaks. A corresponding fluorescent band
and peak for EGFP-VP2-14 was not seen, suggesting that
this construct did not form fluorescent VLPs (fVLPs; Fig.
5A). Dot-blot analysis with monoclonal anti-capsid anti-
body (Fig. 5B) also showed peak patterns in fractions 13–
20 for EGFP-VP2, EGFP-VP2-23 and EGFP-VP2-40. Again,
no signal was seen for EGFP-VP2-14, indicating the lack of
VLP structures for this construct. This characteristic distri-
bution of recombinant viral proteins separated in a
sucrose gradient, then observed by relative fluorescenceJournal of Nanobiotechnology 2006, 4:13 http://www.jnanobiotechnology.com/content/4/1/13
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and dot blot analysis (Fig. 5B) has been previously
reported [20-23]. FCS autocorrelation analysis was per-
formed using a one-component model. The diffusion
time, being the time taken for a particle to travel through
the 0.2 fl laser volume, was close to 1 ms for the EGFP-
VP2, EGFP-VP2-23 and EGFP-VP2-40 fusions giving
hydrodynamic radii of 14–20 nm (Fig. 6 and Table 1). For
the EGFP-VP2-14 construct, the diffusion time was
approximately 0.3 ms corresponding to a hydrodynamic
radius of 7 nm (Fig. 6). EGFP diffused with a calculated
hydrodynamic radius of 2 nm (Table 1). For comparison
of the diffusion times in all constructs, normalized auto-
correlation curves are shown in figure 6. Samples of all
constructs, apart from EGFP-VP2-14, contained VLPs with
a similar size to native CPV. Samples of EGFP-VP2-14 con-
tained smaller particles, too small to be VLPs.
The number of fluorescent units per capsid was measured
for each construct. After incubation of constructs EGFP-
VP2, EGFP-VP2-23 and EGFP-VP2-40 in 6 M urea for 15
min at 50°C, the hydrodynamic radii were reduced to
approximately 10 nm (Table 1) due to disassembly of the
VLPs. A 6 or 10 fold increase in the fluorescent particle
numbers was observed, suggesting at least 10, 6 and 10
fluorescent moieties for EGFP-VP2, EGFP-VP2-23 and
EGFP-VP2-4 VLPs, respectively (Table 1). Followed by
exposure of EGFP-VP2-14 to 6 M urea at 50°C, the fluo-
rescent particle number increased by a factor of 2. These
particles showed a diffusion coefficient consistent with a
globular protein of about 85 kDa, corresponding to a sin-
gle EGFP-VP2-14 fusion protein (Table 1 and Fig. 2B).
Effect of limited proteolysis on the structure of fluorescent 
proteins
The fluorescent fusion constructs, EGFP-VP2, EGFP-VP2-
23, EGFP-VP2-40 and EGFP-VP2-14 were characterized by
FCS before and after treatment with trypsin. The diffusion
times before trypsin treatment (Fig. 7A–C) corresponded
well to the size of typical VLPs (Fig. 6, Table 1). It has been
previously shown that trypsin can be used for cleaving
away the N-terminus of the VP2 protein [24-26]. In the
presence of 8.3 × 10-13 M trypsin (5 min), the diffusion
times were reduced to the 0.1 ms range. The diffusion
times for released particles were the same as compared to
the diffusion time of free EGFP, 0.1 ms (Fig. 6). This
showed that EGFP was completely released from the sur-
face of the fluorescent VLP for EGFP-VP2, EGFP-VP2-23
and EGFP-VP2-40 (Figs. 7A–C). The diffusion coefficient
for EGFP (Table 1) was in agreement with those reported
previously [19,27,28]. Further, the diffusion times were
Schematic representation of truncated forms of the canine parvovirus (CPV) structural protein VP2 and their fusions with the  enhanced green fluorescent protein, EGFP Figure 1
Schematic representation of truncated forms of the canine parvovirus (CPV) structural protein VP2 and their 
fusions with the enhanced green fluorescent protein, EGFP. The N-terminus of VP2 was deleted by 14, 23, and 40 
amino acids and fused to the C-terminus of EGFP resulting in the constructs EGFP-VP2, EGFP-VP2-14, EGFP-VP2-23 and 
EGFP-VP2-40. The non-fused constructs VP2, VP2-14, VP2-23, VP2-40 are presented in the lower panel.
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clearly lower than the diffusion time of the fluorescent
EGFP-VP2-14 protein (0.3 ms; Fig. 6, Table 1), suggesting
that the EGFP-VP2-14 proteins are bigger than free EGFP.
Together, these results suggest that EGFP was exposed on
the surface of the fluorescent VLPs and that EGFP was
released by proteolysis in the presence of 8.3 × 10-13 M
trypsin (Fig. 7).
Discussion
Virus-like particles, VLPs, are multimeric structures that
are morphologically and structurally very similar to their
original viral counterparts. Due to their safety, these types
of reagents or particles have been exploited for e.g. anti-
body detection, as vaccines and antigens and lately also as
gene delivery vehicles [23,29-32]. Various manipulations
of parvoviral structural proteins in order to understand
e.g. structure/function relationships at the molecular/cel-
lular levels have been carried out. These include deletions
of [33] and epitope insertions in the loops of the virion
[34], N-terminal fusion of foreign antigens to VP1
[35,36], N-terminal insertion and fusion [17,19,37] or
Immunoblot analyses of the recombinant proteins Figure 2
Immunoblot analyses of the recombinant proteins. Baculovirus infected Sf9 cells (A and B) expressing the fusion pro-
teins EGFP-VP2, EGFP-VP2-14, EGFP-VP2-23 and EGFP-VP2-40, as well as the non-fused proteins VP2, VP2-14, VP2-23, and 
VP2-40. Sucrose gradient purified proteins are shown in C and D. Proteins were detected with anti-VP2 (A and C) and anti-
GFP (B and D) antibodies. Arrows indicate the recombinant proteins of interest and the molecular weight markers (MW) are 
in kilodaltons (kDa; shown on the left).
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deletions of VP2 [33,38], and C-terminal fusions to VP2
[34,37,39].
Here, N-terminal deletions of the CPV VP2 protein fused
to EGFP i.e. EGFP-VP2-14, EGFP-VP2-23 and EGFP-VP2-
40 were produced in insect cells using the baculovirus
expression vector system (Figs. 1, 2, 3) in order to study
capsid assembly with FCS. The results indicated that all
constructs were able to form capsid-like structures (Figs. 3,
4, 5, 6, 7, 8, Table 1) with sizes closely resembling native
wild-type CPV [22,33,40], except for the EGFP-VP2-14
construct. This was confirmed by electron microscopy
(Fig. 4).
The data obtained from the electron microscopy studies
(Fig. 4) and the FCS measurements (Figs. 6, 7) corre-
sponded well with globular VLPs resembling small spher-
ical virions in the range of 25–50 nm in diameter. By
comparing all of the constructs, a small, but reproducible
deviation in the size and number of the fluorescent fusion
proteins present in the fluorescent VLPs was detected by
FCS (Table 1). When EGFP-VP2 VLPs were analyzed, the
hydrodynamic radius was approximately 17 nm and the
approximate amount of fluorescent moieties per particle
was 10. The hydrodynamic radius of EGFP alone was 2
nm (Table 1). Deletion of the first 14 amino acids from
the N-terminus of VP2 (EGFP-VP2-14) resulted in a dras-
tic change of the hydrodynamic radius from 17 nm to 7
nm with the presence of only 2 fluorescent moieties sug-
gesting that EGFP-VP2-14 lacks the ability of appropriate
assembly. This is interesting, since the other two dele-
tions, i.e. EGFP-VP2-23 and EGFP-VP2-40, are similar in
size compared to the EGFP-VP2 particles containing the
complete VP2 coding sequence (Table 1). The EGFP-VP2-
23 construct, however, was slightly bigger than EGFP-VP2,
having a hydrodynamic radius of 20 nm with about half
(six) the amount of fluorescent particles present in the
capsid. However, the hydrodynamic radius of EGFP-VP2-
Confocal imaging of Sf9 cells infected with recombinant baculoviruses Figure 3
Confocal imaging of Sf9 cells infected with recombinant baculoviruses. (A) AcEGFP-VP2, (B) AcEGFP-VP2-14, (C) 
AcEGFP-VP2-23, (D) AcEGFP-VP2-40, (E) AcVP2, (F) AcVP2-14, (G) AcVP2-23, and (H) AcVP2-40. A monoclonal anti-capsid anti-
body (A4E3) for detection of assembled VP2 was visualized with AlexaFluor® 633-conjugated anti-mouse secondary antibody 
(violet), whereas EGFP (green) was imaged directly. Co-localization of the fusion partners in the merged images is shown in 
white. All images are single confocal midsections from single cells of approximately 0.7 μm in thickness. Bars 2 μm.
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40 was somewhat smaller (14 nm) than that of EGFP-VP2
(17 nm) (Table 1). Further, EGFP-VP2-40 was similar in
size to native CPV [2,4,41].
Previous work by Hurtado and co-workers suggested that
N-terminal deletions of more than 14 amino acids pre-
vents capsid formation, indicating that residues beyond
this point are essential for capsid formation [33]. In addi-
tion to their deletions, an insert of two amino acids (L and
K; leucine and lysine basic, respectively) prior to the trun-
cated VP2 protein was added. These two amino acid inser-
tions could have had an influence on the structure of the
viral protein in order to allow capsid formation. In this
study, deletions of 14 amino acids from the N-terminal
region of VP2 proteins without any insertions of amino
acids, but with a fusion to EGFP appeared not to form
VLPs. However, fusions of EGFP to truncated forms of
VP2 (-23 and -40) did form VLPs. In addition, VP2-14,
VP2-23 and VP2-40 N-terminal deletions could all facili-
tate capsid assembly. Similarly, it has been demonstrated
that most of the N-terminus of human parvovirus B19
VP2, up to 25 amino acids, including the polyglycine
region, could be removed without affecting capsid self-
assembly, but truncations beyond amino acid 30 were
incompatible for either self-assembly or co-assembly with
normal VP2 [38]. These data support the claim that the
amino acids from the residue 14 (A14) to the residue 23
(S23) of VP2 are important for VLP formation, but that
truncations of the CPV VP2 protein could tolerate even
deletions of up to 40 amino acids.
Moreover, within our study an average of 10 fluorescent
fusion protein units in the EGFP-VP2 and EGFP-VP2-40
VLPs, and 6 in the EGFP-VP2-23 VLPs shows similarities
with studies previously reported for the copy number of
the VP1 protein within native CPV capsids [33]. Molecular
models built in this work and existing structural data sup-
port the hypothesis that only one polypeptide may
emerge from each five-fold axis of the capsid giving a max-
imum of 12 EGFP-VP2 fusion protein subunits per capsid
(Fig. 8). Due to the fact that the first 37 amino acids of
CPV VP2 are not structurally resolved, it is difficult to
speculate upon why deletions of the first 14 residues of
VP2 results in a structure unable to form VLPs when fused
to EGFP. However, it is reasonable to suggest that this area
of the peptide (14; A-alanine) is important in CPV VLP
assembly. Fusions at the N-terminus of VP2 may play an
essential role for such chimeric VLPs being able to display
foreign proteins from their icosahedral 5-fold axis. This
has been observed before when only two amino acids
were attached to a deleted CPV VP2 polypeptide of 14
amino acids [33]. Together this suggests the possibility of
replacement of the first 40 amino acids to be used for
designing novel vectors for various display purposes e.g.
for targeting to specific cell types, without interfering with
natural assembly or capsid morphology.
Electron micrographs of negatively stained preparations Figure 4
Electron micrographs of negatively stained preparations. Purified preparations from recombinant baculovirus infected 
Sf9 cells expressing EGFP-VP2, EGFP-VP2-14, EGFP-VP2-23, and EGFP-VP2-40 (upper panel) as well as VP2, VP2-14, VP2-23, 
and VP2-40 (lower panel) are shown. Bars 50 nm.
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Meyer-Almes and co-workers have quite recently shown
that very low enzyme concentrations of target molecules
in FCS can be used [42]. The FCS results presented here
(Fig. 7) show that single fluorescent VLPs were seen at
concentrations of 2 × 10-9 M. In the presence of trypsin at
a concentration of only 8.3 × 10-13 M and after a 5 min
incubation time, the EGFP moieties were completely
released giving one diffusion coefficient identical to that
of EGFP. Thus, the results in terms of the amount of fluo-
rescent moieties per fVLP obtained after the enzyme treat-
ment were similar or identical to those obtained after
treatment with urea at 50°C (data not shown). In con-
trast, a previous report on chimeric CPV VLPs has been
conducted with equal molar ratio of the protease and the
VLPs, 1:1 [24]. Together, the data show that FCS should be
attractive in more general terms when molecular assembly
mechanisms of different VLPs are under study, e.g. when
engineering stable viral vehicles for protein delivery pur-
poses.
Conclusion
Together, the data presented here show that it was possi-
ble to study assembly of a series of truncated and fused
CPV VP2 proteins and also to detect deviations in the abil-
ity of these proteins to assemble into VLPs using FCS. The
non-fluorescent VP2-14, VP2-23, VP2-40 proteins in addi-
tion to the full length VP2 -constructs were all able to form
VLPs. In addition, the fluorescent proteins of EGFPVP2-
23, EGFPVP2-40 and EGFP-VP2 were also able to assem-
ble into VLPs. Interestingly, the VP2-40 construct allowed
better adaptation for the fusion polypeptide to be further
displayed on the surface of the capsid-like structure. There
Fluorescence measurements and dot blot analysis of insect cell lysates exposed to sucrose gradient centrifugation Figure 5
Fluorescence measurements and dot blot analysis of insect cell lysates exposed to sucrose gradient centrifuga-
tion. The samples were produced from Sf9 cells containing EGFP-VP2 (...), EGFP-VP2-14 (-.-), EGFP-VP2-23 (- -) and EGFP-
VP2-40 (—) and the relative fluorescence determined (A). Dot blot analysis of the corresponding fractions using anti-capsid 
(A4E3) antibody detected by AP-conjugated goat anti-rabbit IgG (B). Fractions 1 to 37 (bottom to top) of the gradients are 
indicated below.
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was some proteolysis, as the average number of fluores-
cent fusion molecules per particle was 10, the theoretical
maximum being 12. The 14 amino acid deletion of VP2
fused to EGFP caused a drastic change in the assembly
properties, which was detected by FCS. In conclusion, the
results show that FCS provides a novel platform to study
assembly of viral proteins and, thus, is a valuable technol-
ogy that can be utilized for strategic development of VLPs.
Methods
Plasmid constructs
The DNA sequences of truncated VP2 genes VP2-14, VP2-
23, and VP2-40 were amplified by PCR using pVP2FastBac
[19] as a template with 5 sequences starting from the DNA
corresponding to 14, 23, and 40 amino acids, respectively,
downstream from the N-terminus of VP2. The sense oligo-
nucleotide primers for VP2-14, VP2-23, and VP2-40 were
Fluorescence autocorrelation curves of the fluorescent fusion protein constructs and EGFP Figure 6
Fluorescence autocorrelation curves of the fluorescent fusion protein constructs and EGFP. Normalized autocor-
relation curves of EGFP-VP2, EGFP-VP2-23, EGFP-VP2-40 (τ1), EGFP-VP2-14 (τ2) and soluble EGFP (τ3).
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Table 1: Mobility of fluorescent canine parvovirus recombinant proteins.
Particle τD1 (ms) τD2 (ms) D1 (m2s-1)N o  u r e a ,  R h D1 (nm) 6 M urea, RhD2 (nm) Nf
EGFP-VP2 0.7 ± 0.3 0.3 ± 0.1 1.4 × 10-11 17.0 ± 7.0 8.5 ± 2.7 9.5 ± 0.7
EGFP-VP2-14 0.3 ± 0.0 0.2 ± 0.1 3.6 × 10-11 6.7 ± 0.9 3.9 ± 2.3 2.0 ± 0.1
EGFP-VP2-23 0.8 ± 0.2 0.4 ± 0.1 1.2 × 10-11 20.0 ± 4.0 10.0 ± 2.5 5.8 ± 1.3
EGFP-VP2-40 0.5 ± 0.1 0.4 ± 0.0 1.8 × 10-11 14.0 ± 3.4 9.0 ± 0.7 9.7 ± 0.1
EGFP 0.1 ± 0.0 0.1 ± 0.0 1.2 × 10-10 2.0 ± 0.1 2.0 ± 0.1 1.0 ± 0.0
The diffusion times before (τD1) and after (τD2) treatment with 6 M urea at 50°C, diffusion coefficient (D1), hydrodynamic radii in the absence 
(RhD1) and presence (RhD2) of 6 M urea at 50°C, as well as, the number of fluorescent moieties (Nf) present in the EGFP-VP2, EGFP-VP2-14, EGFP-
VP2-23 and EGFP-VP2-40 fluorescent proteins and VLPs. The enhanced green fluorescent protein (EGFP) served as a reference.Journal of Nanobiotechnology 2006, 4:13 http://www.jnanobiotechnology.com/content/4/1/13
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5'-GGT GGA TCC ATG GTC AGA AAT GAA AGA GC-3', 5'-
GCT GGA TCC ATG GGG AAC GGG TC-3' and 5'-GTG
GGA TCC ATG TCT ACG GGT ACT TTC AAT AAT C-3',
respectively. The anti-sense oligonucleotide primer for
VP2-14, VP2-23, and VP2-40 was 5'-CGA GGC GAA TTC
TTA ATA TAA TTT TCT AGG TGC-3'. The PCR products of
the truncated VP2 genes were digested with BamHI and
EcoRI and cloned into pFastBacI (Gibco BRL, Grand
Island, NY). The resulting plasmids were named pVP2-
14FastBac, pVP2-23FastBac, and pVP2-40FastBac. The
coding sequence of EGFP was amplified as previously
described [19], digested with BamHI and BglII, and then
cloned into the BamHI site of pVP2-14FastBac, pVP2-
23FastBac, and pVP2-40FastBac. For EGFP, the sense oli-
gonucleotide primer was 5'-GTC GGA TCC ATG GTG
AGC AAG GGC G-3' and the anti-sense oligonucleotide
primer 5'-TAA AGA TCT CTT GTA CAG CTC GTC CA-3'.
The resulting plasmids were designated pEGFP-VP2-
14FastBac, pEGFP-VP2-23FastBac and pEGFP-VP2-
40FastBac.
Recombinant baculoviruses
Two sets of recombinant baculoviruses named AcVP2-14,
AcVP2-23, and AcVP2-40 as well as AcEGFP-VP2-14,
AcEGFP-VP2-23, and AcEGFP-VP2-40 were generated
using the Bac-to-Bac system (Gibco BRL) [43,44]. Genera-
tion of the recombinant baculoviruses AcEGFP-VP2 and
AcVP2 has been described previously [19,45].
Production and purification of recombinant proteins
Production and purification of EGFP-VP2, EGFP-VP2-14,
EGFP-VP2-23, and EGFP-VP2-40 recombinant proteins
was conducted essentially as previously described [19]. In
short, 8 × 107 of Sf9 cells (Gibco BRL) in a volume of 40
ml HyQ SFX medium (HyClone Inc., Logan, UT) were
infected with the recombinant viruses, AcEGFP-VP2,
AcEGFP-VP2-14, AcEGFP-VP2-23 and AcEGFP-VP2-40 at
a multiplicity of infection (MOI) of 10. At 72 h post infec-
tion (p.i.), 500 μl samples were analyzed by SDS-PAGE,
immunoblotting and confocal microscopy (see below).
Cells were then collected by low speed centrifugation (1
000 × g, 10 min, 4°C), resuspended on ice for 15 min in
4 ml of ice cold TENT buffer (50 mM Tris-HCl, 10 mM
EDTA, 150 mM NaCl, pH 7.5) containing 0.2% Triton X-
100, 2 mM PMSF (phenylmethylsulphonyl fluoride), 10
μg/ml of aprotinin, 10 μg/ml leupeptin and 10 μg/ml
pepstatin (Sigma-Aldrich, St. Louis, MI). After clarifica-
tion (10 000 × g, 20 min, 4°C), 1 ml samples of the super-
natants were loaded onto 10 – 40% sucrose gradients in
TENT buffer prepared using a Gradient Master™ (Bio-
Comp Instruments, Inc. Canada) and 37 ml ultracentrifu-
gation tubes (Beckman Instruments, San Diego, CA).
Samples were ultracentrifuged (27 000 × g, 12 h, 4°C) and
opalescent or fluorescent bands were detected visually
under visual or UV light and extracted. Bands were then
diluted in PBS, ultracentrifuged (200 000 × g, 1 h, 4°C),
and resultant pellets resuspended in 500 μl ice cold TENT
buffer. Alternatively, gradients were fractionated into 1 ml
aliquots with a peristaltic pump followed by detection of
the recombinant proteins in each fraction by dot blot
analysis using anti-CPV capsid antibody (A4E3) or by flu-
orescence measurements (485 nm excitation, 535 nm
emission, 1 s detection time, Wallac VICTOR2 D Fluorom-
eter, Perkin Elmer Life Sciences Inc., MA).
FCS setup
A confocal fluorescence correlation spectroscope, Confo-
CorII (Carl Zeiss, Jena, Germany) was used to carry out
the FCS experiments. Focusing was performed in LabTek®
II (Nalge Nunc International, Naperville, IL) 8 chamber
borosilicate cell culture plates 200 nm above the coated
glass surface, and the fluorescence was collected through
a Zeiss C-Apochromat 40 × NA 1.2 water immersion
objective. A band pass emission filter (530–600 nm)
through the same objective was used to filter out emitted
photons from the excitation photons.
The effect of trypsin on the fluorescence autocorrelation  curves of the fluorescent recombinant proteins Figure 7
The effect of trypsin on the fluorescence autocorrela-
tion curves of the fluorescent recombinant proteins. 
Normalized autocorrelation curves of EGFP-VP2 (A), EGFP-
VP2-23 (B) EGFP-VP2-40 (C) and EGFP-VP2-14 (D) in the 
absence (...) and presence (—) of 8.3 × 10-13 M trypsin.
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FCS analysis of chemically or enzymatically treated 
recombinant proteins
Preliminary FCS autocorrelation measurements of 10 × 20
s were carried out by diluting the fractions from the
sucrose gradient 1:200 to PBS into the FCS sample cham-
ber. A one-component model for the autocorrelation
analysis was employed for particle size measurements.
The fractions containing particles diffusing with a size cor-
responding to native VP2 VLPs, having the best fits from
the autocorrelation curves, were selected for further anal-
ysis. For EGFP-VP2-14, no sucrose gradient fractions con-
tained VLPs detectable by immunoblotting (Fig. 5) or
contained particles with the size of VLPs when detected by
FCS. Instead, the fractions having the highest count rate in
FCS, 30–35, were pooled for further analysis. For particle
number measurements, fractions 17–20 containing fluo-
rescent VLPs were chosen and further incubated for 15
min at 50°C in the presence of 6 M Urea followed by FCS
analysis. In addition, the corresponding samples (cap-
sids) were diluted to 2 nM concentrations followed by
treatment with 8.3 × 10-13 M trypsin (5 min) and then
analyzed by FCS. Averages and the standard deviations for
the diffusion times were measured and calculated. Diffu-
sion times were used to calculate the diffusion coefficient
D for the sample, using the ratio of the diffusion time of
Rhodamine 6G (Rh6G) dye having a diffusion coefficient
2.8 × 10-6 cm2 s-1, and the diffusion time of the sample
[46]. FCS analysis was carried out in 15 × 40 s measure-
ments repeated 6 times for each sample. All samples were
stored on ice before measurements, and equilibrated 10
min at room temperature (20°C) prior to FCS analysis.
Hydrodynamic properties of particles were calculated by
using the Stokes-Einstein equation D = kT/6πrη, where D
is the diffusion coefficient, r is the hydrodynamic radius,
Models of a fluorescent canine parvovirus virus-like particle Figure 8
Models of a fluorescent canine parvovirus virus-like particle. The model was generated from EGFP-VP2-40, showing 
15 subunits of the virus-like particle. EGFP emerges from the 5-fold axis and nestles onto the cannon structure. Molecular 
model (left) and schematic representation (top right) of the EGFP-VP2-40 recombinant capsid structure. EGFP protrudes 
through the 5-fold axis cannon structures, indicated by white lines, with the central EGFP domain shown in green. Top and side 
views of a 15 mer region of the capsid model are shown (left and bottom right, respectively). VP2-40 polypeptides belonging to 
the same trimers that form single facets of the capsid icosahedron are shown in greens, reds, dark blues, yellows and light 
blues. The EGFP domain is a continuous polypeptide with one of the three VP2-40 domains in each facet of the icosahedral 
capsid structure, with the EGFP of the other two VP2-40 polypeptides removed by proteolysis before or during capsid assem-
bly. The EGFP domains could be located at all or some of the twelve cannon structures, depending on proteolysis.
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η is the viscosity of the solvent, T is the temperature and k
is Boltzman's constant.
SDS-PAGE and immunoblotting
Samples [47] were separated on 12% slab gels and trans-
ferred to nitrocellulose sheets (Schleicher & Schuell Bio-
Science, Inc., Keene, NH) for immunoblot analysis.
Proteins were identified with rabbit polyclonal anti-VP2
antibodies (Cornell #2 antibody, kind gift from Dr. Colin
Parrish), a mouse monoclonal anti-CPV capsid antibody
A4E3 (dot-blot), or with rabbit polyclonal anti-GFP anti-
bodies (Promega, Madison, WI). Proteins were visualized
with AP-conjugated goat anti-rabbit IgG (Promega) and
with NBT (nitro blue tetrazolium) and BCIP (5-bromo-4-
chloro-3-indolylphosphate; Sigma-Aldrich). Molecular
weight markers were from BioRad.
Immunolabeling of Sf9 cells
Infected insect cells were collected by low speed centrifu-
gation (800 × g, 1 min, RT), washed twice with PBS (pH
7.4) prior to fixation in 50 μl of 4% PFA-PBS (20 min, RT)
and then pelleted (10 000 × g, 1 min, RT). Before immu-
nostaining, cells were rinsed twice with 50 μl of 0.15%
glycine in PBS with a centrifugation step (10 000 × g, 1
min, RT) between each wash. Fixed cells were permeabi-
lized (1% BSA, 0.1% Triton X-100 and 0.01% sodium
azide in PBS) for 20 min at RT and pelleted (10 000 × g, 1
min, RT). A mouse monoclonal anti-capsid antibody,
A4E3 (kind gift from Dr. Colin Parrish) was used to iden-
tify VP2. After incubation with the anti-capsid antibody,
cells were washed 3 times in 50 μl PBS and the viral pro-
teins probed with a fluorescently conjugated secondary
antibody (goat AlexaFluor®  633 anti-mouse antibody,
Molecular Probes, Eugene, OR). After fluorescent staining,
cells were washed twice with 50 μl PBS and pelleted (10
000 × g, 1 min, RT). Finally, cells were embedded in 2–7
μl of MOWIOL-DABCO (30 mg/ml; Sigma-Aldrich) and
cover slips were left for 2–24 h at 4°C before examination
under a confocal laser scanning fluorescence microscope
(Axiovert 100 M, LSM510, Carl Zeiss, Jena, Germany)
with excitation and emission settings appropriate for the
dyes used according to the manufacturer's instructions.
Electron microscopy
Specimens for electron microscopy (EGFP-VP2, EGFP-
VP2-14, EGFP-VP2-23, EGFP-VP2-40, VP2, VP2-14, VP2-
23, and VP2-40) were prepared from the samples
obtained by sucrose gradient purification. Resuspended
samples (6 μl) were applied to carbon coated copper grids
and left to stand for 1–2 min at RT. After excess liquid was
blotted away, grids were negatively stained with 6 μl 2%
potassium phosphotungstate, pH 6. Excess liquid was fur-
ther removed and grids left to dry at RT. Samples were
examined at 60 kV under a JEOL JEM-1200 EX transmis-
sion electron microscope (Jeol Ltd. Tokyo, Japan).
Molecular modelling
A molecular model of EGFP-VP2-40 was constructed
based on the crystal structures of EGFP (PDB 1EMF) and
CPV VP2 (PDB 4DPV) with a surrounding 14 subunits of
VP2 (PDB 1C8D), to form a 15-mer around one 5-fold
axis, through which the N-terminus of VP2-40 protrudes,
carrying the EGFP domain. Models were built in Insight II
(Accelrys) and graphics were rendered using Pymol 0.98
(Delano, W.2. The Pymol molecular Graphics System
2002).
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